Clinical Trial Update: A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Patients [Phase 2]

View source ↗

Summary

A single-arm Phase II trial assessing simvastatin added to XELOX and bevacizumab as first-line therapy in metastatic colorectal cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• SIMVASTATIN (SIMVASTATIN)
• XELOX (capecitabine + oxaliplatin)

Snippet

Sponsor: Samsung Medical Center | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED